4.7 Article

Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 12, Issue 12, Pages 1958-U42

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2014.09.028

Keywords

-

Funding

  1. National Institutes of Health/National Cancer Institute [U54CA163308-01]
  2. National Cancer Institute

Ask authors/readers for more resources

Precise diagnostic coding of procedures is of critical importance for accurate billing, determination of patient co-pays and deductibles, retrospective analysis of results, and development of performance metrics. For example, whether a colonoscopy is coded as diagnostic or therapeutic, screening or surveillance has important implications for determining patient's personal cost, deriving an endoscopists' adenoma detection rate and understanding appropriate use of the procedure. In this month's Practice Management: The Road Ahead article, Dr. Amit G. Singal and colleagues help us wade through the terminology and implications of procedural coding. As more refined electronic reporting systems are developed, we hope that standardization of terminology becomes more robust. Only with a more standardized coding and indication documentation can we hope to derive accurate population level information.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Risk factors for HCC in contemporary cohorts of patients with cirrhosis

Fasiha Kanwal, Saira Khaderi, Amit G. Singal, Jorge A. Marrero, Nicole Loo, Sumeet K. Asrani, Christopher Amos, Aaron P. Thrift, Xiangjun Gu, Michelle Luster, Abeer Al-Sarraj, Jing Ning, Hashem B. El-Serag

Summary: This study investigated the risk of developing HCC in patients with cirrhosis and found that the incidence rate of HCC was lower than previously reported. The risk of HCC varied depending on the etiology, with higher risk in patients with cured HCV and lower risk in those with NAFLD. Current smoking and overweight/obesity were also associated with increased HCC risk.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States

Nikita Sandeep Wagle, Sulki Park, David Washburn, Robert L. Ohsfeldt, Nicole E. Rich, Amit G. Singal, Hye-Chung Kum

Summary: This study found that treatment delays are prevalent in patients with hepatocellular carcinoma (HCC) and are associated with worse survival. Treatment delays varied across different treatment modalities and were more likely to occur in Black patients and those living in high poverty neighborhoods. The results highlight the importance of interventions to improve time-to-treatment.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Oncology

Survival of cancer survivors with a new pancreatic cancer diagnosis

Sandi L. Pruitt, Anna Tavakkoli, Hong Zhu, Daniel F. Heitjan, David E. Gerber, Amit G. Singal, Ethan A. Halm, Muhammad Shaalan Beg, Bhumika Maddineni, Ankit J. Kansagra, Caitlin C. Murphy

Summary: Pancreas cancer patients who have previously had another cancer have similar survival rates to those without previous cancer, suggesting that cancer survivors should be considered for inclusion in pancreas cancer clinical trials.

CANCER MEDICINE (2023)

Article Oncology

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis

Andrew M. Brown, Ihab Kassab, Marco Massani, Whitney Townsend, Amit G. Singal, Cigdem Soydal, Laura Moreno-Luna, Lewis R. Roberts, Vincent L. Chen, Neehar D. Parikh

Summary: This study conducted an overall and individual patient data (IPD) meta-analysis of transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). The results showed that TARE had a significantly longer time to progression (TTP) compared to TACE, but there was no significant difference in overall survival (OS) between the two modalities. The limitations of the current data include inconsistent length of follow-up and response criteria. Therefore, prospective studies comparing these treatments are needed.

CANCER MEDICINE (2023)

Editorial Material Gastroenterology & Hepatology

Precision HCC Surveillance: It Is All in the Number (Needed)

Amit G. Singal, Neehar D. Parikh, Yujin Hoshida

DIGESTIVE DISEASES AND SCIENCES (2023)

Review Gastroenterology & Hepatology

Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?

Neehar D. Parikh, Nabihah Tayob, Amit G. Singal

Summary: Hepatocellular carcinoma (HCC) is a major contributor to cancer-related deaths globally due to inadequate early detection strategies. Current screening recommendations have several deficiencies, including suboptimal sensitivity and poor adherence. Blood-based biomarkers show promise but require validation and logistical solutions before clinical implementation. Maturing validation cohorts, such as the Hepatocellular Carcinoma Early Detection Study and the Texas Hepatocellular Carcinoma Consortium, are expected to provide robust validation for candidate biomarkers.

JOURNAL OF HEPATOLOGY (2023)

Article Public, Environmental & Occupational Health

In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18 000 adult offspring

Caitlin C. Murphy, Piera M. Cirillo, Nickilou Y. Krigbaum, Amit G. Singal, Dean P. Jones, Timothy Zaki, Barbara A. Cohn

Summary: This study examined the association between in-utero exposure to antibiotics and the risk of colorectal cancer (CRC) in adult offspring. The findings suggest that in-utero exposure to long-acting sulfonamides is associated with an increased risk of CRC in adulthood.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2023)

Article Gastroenterology & Hepatology

Colorectal Cancer Risk Assessment and Precision Approaches to Screening: Brave New World or Worlds Apart?

Fay Kastrinos, Sonia S. Kupfer, Samir Gupta

Summary: Current colorectal cancer (CRC) screening recommendations are based on age, but precision screening using additional factors could improve outcomes and resource utilization. Prediction models can identify high-risk groups for more intensive screening and low-risk groups for less invasive screening. Developing reliable and accurate prediction models and studying their feasibility and cost-effectiveness are critical for future implementation of precision CRC screening.

GASTROENTEROLOGY (2023)

Article Multidisciplinary Sciences

Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score

Aaron P. Thrift, Fasiha Kanwal, Yanhong Liu, Saira Khaderi, Amit G. Singal, Jorge A. Marrero, Nicole Loo, Sumeet K. Asrani, Michelle Luster, Abeer Al-Sarraj, Jing Ning, Spiridon Tsavachidis, Xiangjun Gu, Christopher I. Amos, Hashem B. El-Serag

Summary: This study found that polygenic risk scores can be used to predict the risk of hepatocellular cancer in contemporary U.S. cirrhosis patients and can improve the predictive ability of traditional risk factor models.

PLOS ONE (2023)

Article Chemistry, Multidisciplinary

Discovery of Core-Fucosylated Glycopeptides as Diagnostic Biomarkers for Early HCC in Patients with NASH Cirrhosis Using LC- HCD-PRM-MS/MS

Yifei Tan, Jianhui Zhu, Cristian D. Gutierrez Reyes, Yu Lin, Zhijing Tan, Zuowei Wu, Jie Zhang, Alva Cano, Sara Verschleisser, Yehia Mechref, Amit G. Singal, Neehar D. Parikh, David M. Lubman

Summary: Aberrant changes in site-specific core fucosylation (CF) of serum proteins can serve as potential diagnostic markers of tumors. A study employed an optimized data-dependent acquisition (DDA) workflow to identify CF of serum proteins in patients with nonalcoholic steatohepatitis-related cirrhosis and hepatocellular carcinoma. The study found significant changes in CF peptides between cirrhosis and HCC, with one peptide showing the best diagnostic performance in discriminating HCC from cirrhosis.

ACS OMEGA (2023)

Article Gastroenterology & Hepatology

Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study

Amit G. Singal, T. Tara Ghaziani, Neil Mehta, Kali Zhou, Lauren T. Grinspan, Jihane N. Benhammou, Andrew M. Moon, Ju Dong Yang, Reena Salgia, Anjana Pillai, Elizabeth Zheng, Nicole E. Rich, Purva Gopal, Prasun Jalal, Elizabeth Verna, Sruthi Yekkaluri, Samuel Phen, Jonathan Melendez-Torres, Omar Alshuwaykh, Hailey Choi, Kevin Junus, John Grady, Michael Song, Emily A. Leven, Jung Yum, Vrushab Gowda, Manaf Alsudaney, Perla Hernandez, Nirmal Desai, Neehar D. Parikh

Summary: There is a wide variation in recall patterns for patients with subcentimeter liver lesions on ultrasound. The low risk of primary liver cancer (PLC) in these patients supports short-interval ultrasound follow-up in 3-6 months, but high-risk subgroups may require diagnostic CT/MRI.

HEPATOLOGY COMMUNICATIONS (2023)

Article Oncology

In utero exposure to antiemetic and risk of adult-onset colorectal cancer

Caitlin C. Murphy, Piera M. Cirillo, Nickilou Y. Krigbaum, Amit G. Singal, Barbara A. Cohn

Summary: This study found that offspring exposed to Bendectin in utero had a higher risk of colorectal cancer (CRC) compared to unexposed offspring. The increased risk may be due to the presence of dicyclomine in Bendectin. Further experimental studies are needed to confirm these findings and identify the mechanisms of risk.

JNCI CANCER SPECTRUM (2023)

Article Gastroenterology & Hepatology

Breakthroughs in Hepatocellular Carcinoma Therapies

Amit G. Singal, Masatoshi Kudo, Jordi Bruix

Summary: Breakthroughs in HCC therapy, including surgical and local ablative therapies, have expanded the number of eligible patients for curative-intent procedures. Transarterial chemoembolization (TACE) remains the treatment of choice for liver-localized disease, but there is increasing recognition of patients who may benefit from systemic therapy. Systemic therapy, especially immune checkpoint inhibitor combinations, has shown promising results with objective responses in approximately 30% of patients and improved survival. Multidisciplinary care is critical for complex decision-making and improved clinical outcomes in HCC treatment. Further research is needed to explore combination therapies and identify remaining areas of need.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Multidisciplinary Sciences

Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort

Noa Kopplin, Angie Garcia, Annika Reczek, Kate Wilkinson, Sruthi Yekkaluri, Caitlin C. Murphy, Jasmin Tiro, Alagar R. Muthukumar, Andrew Masica, Amit G. Singal

Summary: This study investigated the natural history and sequelae symptoms of mild COVID-19 infection. More than one in five patients reported persistent symptoms during follow-up. Levels of anti-nucleocapsid and anti-spike antibodies decreased within six months following infection and vaccination.

PLOS ONE (2023)

Article Gastroenterology & Hepatology

Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study

Andrew M. Moon, Sarah Cook, Rachel M. Swier, Hanna K. Sanoff, Michael D. Kappelman, Lynne I. Wagner, A. Sidney Barritt, Amit G. Singal, Neil D. Shah, David M. Mauro, Ted K. Yanagihara, David A. Gerber, Michael W. Fried, Cristal Brown, Myra Waheed, Randall Teal, Donna M. Evon

Summary: This study found that posttreatment symptoms after locoregional therapies in HCC patients are common and often severe. These findings can help prioritize patient-reported outcomes (PRO) domains and suggest that patients are interested in electronic PRO symptom monitoring. Further investigation of electronic PRO monitoring in HCC patients is warranted.

HEPATOLOGY COMMUNICATIONS (2023)

No Data Available